Expected Moves

The Read: Anavex’s stock has historically dropped sharply on earnings releases despite meeting or beating EPS estimates due to investor disappointment with qualitative updates like cash runway clarity and leadership changes, but rallied about 22% on a favorable EMA re-examination decision for blarcamesine before retreating post-event.